Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis-Reference-Cited by-同舟云学术

Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis

Published:2019-10 Issue:2 Volume:49 Page:204-210
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Ishikawa Yuki^ORCID,Hashimoto Motomu,Ito Hiromu,Tanaka Masao,Yukawa Naoichiro,Fujii Takao,Yamamoto Wataru,Mimori Tsuneyo,Terao Chikashi

Funder

Daiichi Sankyo Co. Ltd

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference24 articles.

1. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study;Yukawa;Arthritis Res Ther,2011

2. One year in review 2018: pathogenesis of rheumatoid arthritis;Calabresi;Clin Exp Rheumatol,2018

3. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis;Nam;Ann Rheum Dis,2017

4. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation;Malottki;Health Technol Assess,2011

5. Biologics-induced autoimmune diseases;Perez-Alvarez;Curr Opin Rheumatol,2013

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between serum antinuclear antibody and rheumatoid arthritis;Frontiers in Immunology;2024-04-22

2. Baseline ANA and Anti‐Ro60/SSA Antibody as Potential Predictors for Immunogenicity and Poor EULAR Response in Adalimumab‐Treated RA Patients;Journal of Clinical Pharmacy and Therapeutics;2024-01

3. AB0418 ELEVATED ANA AS A PREDICTOR OF THERAPEUTIC FAILURE TO BIOLOGICAL ANTI-TNF AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS;Scientific Abstracts;2023-05-30

4. Clinical Relevance of Autoantibodies and Inflammatory Parameters in Non-infectious Scleritis;Ocular Immunology and Inflammation;2021-08-31

5. Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis;ACR Open Rheumatology;2021-05-31